Analyst Ratings For NASDAQ:CBAY – CymaBay Therapeutics (NASDAQ:CBAY)
Today, HC Wainwright raised its price target on NASDAQ:CBAY – CymaBay Therapeutics (NASDAQ:CBAY) to per share.
Some recent analyst ratings include
- 3/16/2018-SunTrust Banks Reiterated Rating of Buy.
- 3/16/2018-Piper Jaffray Reiterated Rating of Buy.
- 3/16/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 2/13/2018-Evercore ISI initiated coverage with a Outperform rating.
Recent Insider Trading Activity For NASDAQ:CBAY – CymaBay Therapeutics (NASDAQ:CBAY)
NASDAQ:CBAY – CymaBay Therapeutics (NASDAQ:CBAY) has insider ownership of 15.10% and institutional ownership of 58.15%.
- On 7/19/2018 Kurt Von Emster, Director, bought 153,846 with an average share price of $6.50 per share and the total transaction amounting to $999,999.00.
- On 3/22/2018 Carl Goldfischer, Director, sold 15,000 with an average share price of $13.03 per share and the total transaction amounting to $195,450.00.
- On 3/5/2018 Kurt Von Emster, Director, sold 13,353 with an average share price of $15.51 per share and the total transaction amounting to $207,105.03.
- On 2/14/2018 Kurt Von Emster, Director, sold 218,057 with an average share price of $15.89 per share and the total transaction amounting to $3,464,925.73.
- On 2/7/2018 Kurt Von Emster, Director, sold 40,763 with an average share price of $12.35 per share and the total transaction amounting to $503,423.05.
- On 2/5/2018 Kurt Von Emster, Director, sold 18,831 with an average share price of $12.14 per share and the total transaction amounting to $228,608.34.
- On 2/2/2018 Kurt Von Emster, Director, sold 90,098 with an average share price of $12.15 per share and the total transaction amounting to $1,094,690.70.
Recent Trading Activity for NASDAQ:CBAY – CymaBay Therapeutics (NASDAQ:CBAY)
Shares of NASDAQ:CBAY – CymaBay Therapeutics closed the previous trading session at 13.16 up +0.07 0.53% with 13.260000228881836 shares trading hands.